Observational studyJournal of the American Heart Association2025
Natural History of Tricuspid Regurgitation After Transcatheter Aortic Valve Implantation.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Impact of Pacemaker Implantation in Transcatheter Aortic Valve Replacement With Self-Expanding Prosthesis.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTo determine the impact of tricuspid regurgitation (TR) on outcomes after transcatheter aortic valve implantation (TAVI), and to determine the evolution of TR severity after TAVI.
methodsThis was an observational study of TAVIs for aortic stenosis from November 2012 to December 2021. Patients were dichotomized according to the severity of pre-TAVI TR: less than moderate versus moderate or greater. Logistic regression was used to determine the risk factors for progression or persistence of moderate or greater TR at 1 year after TAVI.
resultsA total of 2250 patients were included for analysis, of which 301 (13.4%) had moderate or greater TR before TAVI. Baseline moderate or greater TR was associated with reduced survival and a higher incidence of heart failure readmission at 5 years after TAVI. Twelve percent of patients had progression or persistence of moderate or greater TR at 1 year after TAVI. On multivariable logistic regression, increasing age, female sex, lower mean pre-TAVI aortic transvalvular pressure gradient, pulmonary artery systolic pressure ≥40 mm Hg, pulmonary vascular disease, and transfemoral vascular access were associated with progression or persistence of moderate or greater TR at 1 year after TAVI, while periprocedural variables related to valve implantation were not.
conclusionsSignificant TR before TAVI was associated with poor outcomes after TAVI. The incidence of moderate or greater TR at 1 year after TAVI was reasonable at 12%. Periprocedural factors, such as valve size, type of implanted valve, and paravalvular leak, were not associated with the development of TR. Evolution of TR and heart failure symptoms must be carefully surveilled after TAVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.